UNSPSC 51112020: Ceritinib

A kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

UNSPSC 51112020 Ceritinib, a Commodity code, covers pharmaceutical supply contracts through state and local cooperative purchasing vehicles, where recent activity centers on establishing statewide or multistate frameworks for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to government facilities. The scope includes manufacturer direct-supply agreements requiring detailed product specifications, National Drug Codes, SKUs, packaging configurations, and manufacturing location data, with vendors competing primarily on price competitiveness (75 percent of evaluation weight) while meeting compliance standards for Good Manufacturing Practices, Drug Supply Chain Security Act certification, and FDA requirements. Issuing bodies are multistate cooperative purchasing alliances administering pharmaceutical procurement on behalf of participating state agencies, counties, cities, and other government entities across member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the most recent relevant opportunity on January 20, 2026—a Request for Proposal titled "MMCAP Generic Multi Source Pharmaceuticals and OTC Products" (S1070000015802) with a response deadline of March 26, 2026. The RFP establishes multiple contracts effective July 1, 2026, requiring vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), carry insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability per occurrence, and accept a 3 percent administrative fee on all contract purchases. The contract term spans two years for new responders with optional extensions, while incumbent responders align with existing expiration dates through June 30, 2028. MMCAP reserves award discretion across sole, dual, or multi-award structures based on therapeutic considerations and member-specific needs, with no disclosed award value or budget range in available materials.